Clinical trials · New York
Cancer clinical trials in New York
We’re tracking 1,365 recruiting cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
New York, New YorkAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Cooperstown, New YorkAges 18 years+ - NCT06528496RecruitingPhase 2
Less chemo plus antibody therapy for high-risk neuroblastoma in children
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
New York, New YorkAges 1.5 years–19 years - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Commack, New YorkAges 18 years+ - NCT04879329RecruitingPhase 2
Study for HER2-positive bladder cancer after limited treatment
This Phase 2 trial tests disitamab vedotin alone or with pembrolizumab for urothelial (bladder/urinary tract) cancer that has HER2-positive tumors. It aims to shrink tumors and improve outcomes, including for people who have had limited prior treatment or specific prior drug exposures.
Commack, New YorkAges 18 years+ - NCT03546387Recruiting
Anesthesia and brain thinking changes in children with retinoblastoma
This study looks at whether having anesthesia more than once (for eye/surgery treatment) affects children’s thinking and learning. It may help doctors plan safer care and better follow-up for children with retinoblastoma.
New York, New YorkAges 6–17 - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT04364503Enrolling by invitation
Study that analyzes de-identified patient samples and records
This trial checks how well patient samples and health records can be analyzed when names are removed (“de-identified”) and privacy rules are followed. You might be included if you agree in writing and your sample data can be used for this research and/or your doctor requests it.
Buffalo, New YorkAges Any age - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Albany, New YorkAges 1–21 - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
New York, New YorkAges 18 years+ - NCT06088771RecruitingPhase 1/Phase 2
Study of dupilumab and cemiplimab before lung cancer surgery
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
New York, New YorkAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
New York, New YorkAges 18 years+ - NCT06863402RecruitingPhase 2
Study of two drugs for Richter transformation lymphoma
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Buffalo, New YorkAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
New York, New YorkAges 18 years+ - NCT06564038RecruitingPhase 1/Phase 2
Study of AZD0486 alone or with other drugs for B-cell cancers
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
New York, New YorkAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
Lake Success, New YorkAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
New York, New YorkAges 18 years+ - NCT07711847Recruiting
Prone positioning for faster breast radiation therapy
This trial tests a personalized prone-immobilization device for partial breast radiation after surgery. It aims to make treatment more comfortable and accurate for patients who have had breast-conserving surgery.
New York, New YorkAges 40 years+ - NCT04968834Recruiting
Collecting children’s and young adults’ blood and marrow for genetic testing
This study collects and stores blood and bone marrow samples from young people with certain blood cancers so doctors can do genetic (“genomic”) testing now and in the future. It may help improve understanding of the disease and support better matching of care for patients.
Albany, New YorkAges Up to 30 years - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Commack, New YorkAges 18 years+ - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Buffalo, New YorkAges 18 years+ - NCT04981821Recruiting
Mobile exercise coaching for older adults with blood cancers
This study tests whether a mobile (phone-based) exercise program can help older adults with myeloid blood cancers stay active and function better while they receive outpatient cancer treatment. You may be asked to follow an exercise plan and participate in assessments during the trial.
Rochester, New YorkAges 60 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
New York, New YorkAges 18 years+
Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- Memorial Sloan Kettering Nassau · 4 studies
- NYU Langone Health · 4 studies
- Roswell Park Cancer Institute · 4 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- State University of New York Upstate Medical University · 3 studies
- Albany Medical Center · 2 studies
- Columbia University Irving Medical Center · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in New York?
- Yes. We're currently tracking 1,365 recruiting cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.